Literature DB >> 16162850

Pharmacologic and toxicologic evaluation of C. novyi-NT spores.

Luis A Diaz1, Ian Cheong, Catherine A Foss, Xiaosong Zhang, Brock A Peters, Nishant Agrawal, Chetan Bettegowda, Baktiar Karim, Guosheng Liu, Khalid Khan, Xin Huang, Manu Kohli, Long H Dang, Paul Hwang, Ahava Vogelstein, Elizabeth Garrett-Mayer, Barry Kobrin, Martin Pomper, Shibin Zhou, Kenneth W Kinzler, Bert Vogelstein, David L Huso.   

Abstract

Clostridium novyi-NT (C. novyi-NT) spores have been shown to be potent therapeutic agents in experimental tumors of mice and rabbits. In the present study, pharmacologic and toxicologic studies were performed to better understand the factors influencing the efficacy and toxicity of this form of therapy. We found that spores were rapidly cleared from the circulation by the reticuloendothelial system. Even after large doses were administered, no clinical toxicity was observed in healthy mice or rabbits. The spores were also not toxic in mice harboring poorly vascularized non-neoplastic lesions, including myocardial infarcts. In tumor-bearing mice, toxicity appeared related to tumor size and spore dose, as expected with any bacterial infection. However, there was no laboratory or histopathologic evidence of sepsis, and the toxicity could be effectively controlled by simple hydration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162850     DOI: 10.1093/toxsci/kfi316

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  33 in total

1.  Structural characterization of the polar lipids of Clostridium novyi NT. Further evidence for a novel anaerobic biosynthetic pathway to plasmalogens.

Authors:  Ziqiang Guan; Norah C Johnston; Semra Aygun-Sunar; Fevzi Daldal; Christian R H Raetz; Howard Goldfine
Journal:  Biochim Biophys Acta       Date:  2010-12-30

Review 2.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

3.  Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Authors:  Nicholas J Roberts; Linping Zhang; Filip Janku; Amanda Collins; Ren-Yuan Bai; Verena Staedtke; Saurabh Saha; Shibin Zhou; Anthony W Rusk; David Tung; Maria Miller; Jeffrey Roix; Kristen V Khanna; Ravi Murthy; Robert S Benjamin; Thorunn Helgason; Ariel D Szvalb; Justin E Bird; Sinchita Roy-Chowdhuri; Halle H Zhang; Yuan Qiao; Baktiar Karim; Jennifer McDaniel; Amanda Elpiner; Alexandra Sahora; Joshua Lachowicz; Brenda Phillips; Avenelle Turner; Mary K Klein; Gerald Post; Luis A Diaz; Gregory J Riggins; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda; David L Huso; Mary Varterasian
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

Review 4.  Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Authors:  Verena Staedtke; Ren-Yuan Bai; Jaishri O'Neill Blakeley
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

5.  Bacteriolytic therapy of experimental pancreatic carcinoma.

Authors:  Claudia Maletzki; Michael Gock; Ulrike Klier; Ernst Klar; Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

Review 6.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Authors:  Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary-Jo Dorie; Adam V Patterson; J Martin Brown
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 8.  Bacteria in cancer therapy: a novel experimental strategy.

Authors:  S Patyar; R Joshi; D S Prasad Byrav; A Prakash; B Medhi; B K Das
Journal:  J Biomed Sci       Date:  2010-03-23       Impact factor: 8.410

Review 9.  Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.

Authors:  Guoying Ni; Tianfang Wang; Lin Yang; Yuejian Wang; Xiaosong Liu; Ming Q Wei
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

10.  Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.

Authors:  Yunlei Zhang; Youming Zhang; Liqiu Xia; Xiangli Zhang; Xuezhi Ding; Fu Yan; Feng Wu
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.